Clinical Trials
23 trialsTrial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
PanCAN-SR1
Pancreatic Cancer Action Network
CISPD-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Beijing 302 Hospital
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
RISE-HN
National Taiwan University Hospital
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
University of Pittsburgh
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Chinese PLA General Hospital